PDCD1 and non-small cell lung carcinoma: Currently, anti-PD-1/PD-L1 therapy has been approved for the treatment of various tumors, including CRC, HCC, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), as well as head and neck cancer (HNC), among others (23).